ReviewAntibiotics (Basel, Switzerland)2021
Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 103 citations in OpenAlex.
- A novel stress response pathway mediates biofilm architecture in Pseudomonas aeruginosa.PLoS pathogens · 2026Article
- Host-Pathogen Interactions in Cystic Fibrosis Lung Disease: Adaptation, Persistence, and Clinical Implications ofPathogens (Basel, Switzerland) · 2026Review
- Mucolytic Core-Shell Particles to Boost Levofloxacin Penetration Through the Mucus Barrier in Cystic Fibrosis.Pharmaceutical research · 2026Article
- Quorum Sensing and Quorum Quenching in Pseudomonas aeruginosa and Staphylococcus aureus Infections: Therapeutic Potential, Limitations and Clinical Challenges.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.Open forum infectious diseases · 2026Review
- Extracellular Particles Derived From Mesenchymal Stromal Cells ReduceJournal of extracellular biology · 2026Article
- Sublethal Antibiotic Exposure Induces Microevolution of Quinolone Resistance in PathogenicInternational journal of molecular sciences · 2026Article
- HuR-Targeted Small Molecules ReduceInternational journal of molecular sciences · 2025Article
- Farnesol emulsion for elimination ofBiofilm · 2025Article
- The role of salivary biochemical markers and dental indices in the assessment of oral health of Egyptian children with cystic fibrosis: an exploratory study.Scientific reports · 2025Article
- Harnessing machine learning to predict antibiotic susceptibility in Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Article
- Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study.Antimicrobial agents and chemotherapy · 2025Article
- Mesenchymal stromal cell extracellular vesicles reduceAmerican journal of physiology. Lung cellular and molecular physiology · 2025Article
- Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.Journal of bacteriology · 2025Review
- Effect of Tobramycin on the Biofilm-Forming Forms of Pseudomonas aeruginosa Isolates Isolated from Patients with Cystic Fibrosis.Bulletin of experimental biology and medicine · 2025Article
- In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-ResistantJournal of clinical medicine · 2025Article
- Biofilm Formation ofMicroorganisms · 2025Review
- Impact of Modulator Therapy on the Chronic Colonization of Lower Respiratory Tract Pathogens in Children: Data From Cystic Fibrosis Registry of Turkey.Pediatric pulmonology · 2025Article
- Aspartic acid unveils as antibiofilm agent and tobramycin adjuvant against mucoid and small colony variants ofBiofilm · 2025Article
- Let-7b-5p loaded Mesenchymal Stromal Cell Extracellular Vesicles reducebioRxiv : the preprint server for biology · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics, i.e., colistin, tobramycin, aztreonam lysine and levofloxacin, are used as maintenance treatment for CF patients after the development of chronic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.